Nancy Gough
•
Nancy R. Gough is the owner of BioSerendipity (www.bioserendipity.com). A Ph.D. scientist with a passion for scientific communication and incredible scientific curiosity, her scientific expertise spans basic research in the life sciences to translational medicine. After 17 years with the American Association for the Advancement of Science (AAAS), Dr. Gough stepped down as the Editor of Science Signaling (a weekly multidisciplinary journal) and launched her company. Through BioSerendipity, she serves as a scientific consultant for researchers, a consultant to scholarly publishers and scientific organizations, and a freelance writer and editor. She has a Ph.D. in Pharmacology and Experimental Therapeutics from the University of Maryland Medical School. After graduating, she joined Johns Hopkins University, first as a postdoctoral fellow, then as a research associate, in the lab of Dr. Douglas Fambrough in the Biology Department. She performed research in cell biology, as well as taught undergraduate and graduate courses.
![](https://media.datadriveninvestor.com/uploads/2020/08/20200817141226-Gough_GlassesSqURE-Nancy-Gough-150x150.jpg)
3 Stories by Nancy Gough
The currently available vaccines do not prevent a person from becoming infected with SARS-CoV-2. They give your immune system an introduction to the virus...
Too much histamine or prostaglandin D2 signaling or too little interferon signaling lead to increased risk for severe COVID-19. An imbalanced immune response appears...
Lyme disease vaccine induces antibodies in Phase II clinical trial. SHORT SUMMARY: The engineered protein vaccine VLA15 induces multiple antibodies in a Phase II trial...